DP14 ALK-positive histiocytosis with involvement confined to the skin: report of two cases in adults
Su Xin Lim,Sarajeni Pugalenthy,Niall Wilson,Cristina Vasile,Arti Bakshi,Stuart Cohen
DOI: https://doi.org/10.1093/bjd/ljae090.236
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract We present two interesting cases of anaplastic lymphoma kinase (ALK)-positive histiocytosis in adults. The first was a 79-year-old woman with a 10-year history of a firm, violaceous, exophytic nodule on her right upper arm. It was asymptomatic, and stable in size and colour. It measured 11 mm in diameter and had a scaly surface. Dermoscopy was nondiagnostic, showing a featureless, violaceous appearance. Histology revealed a dermal histiocytic infiltrate with epithelioid and foamy histiocytes and occasional Touton-type giant cells. Immunohistochemistry showed the histiocytes to be CD68 and ALK positive (clone AlkD5F3). S100 and CD1a were negative. The second case was a 42-year-old man with an enlarging, latterly tender lesion on the chest for many years. Examination showed a nonspecific 5 × 4-mm shiny pink papule. Excision histology revealed a dermal histiocytic infiltrate, with numerous lymphocytes and focal emperipolesis. Immunohistochemistry showed the histiocytes to be CD68 and S100 positive with patchy ALK positivity (clone AlkD5F3). CD1a was negative. A diagnosis of ALK-positive histiocytosis was concluded in both cases. This rare subtype involves a genetic alteration in genes encoding receptor tyrosine kinases. Its full clinicopathological features have not been fully elucidated. It most commonly presents in young infants as a multisystem disease with liver and haematological disturbances. Localized disease is more common in adults, for which the prognosis is good. Clinicopathological correlation is important as the clinical features are usually nonspecific. Previous reports involving cutaneous disease have tended to focus on extracutaneous manifestations, although papules, which may be yellow or purple, at various sites have been described. Symptoms from the skin lesions have not been clearly reported. Histopathologists need to be aware of this new entity and include ALK immunostain in all dermal histiocytic lesions. The morphology is variable, consisting of an admixture of epithelioid and foamy histiocytes, sometimes with emperipolesis and thus mimicking juvenile xanthogranuloma and Rosai–Dorfman disease morphologically. Previous cases have found gene fusions of KIF5B–ALK, TPM3–ALK, CLTC–ALK, TFG–ALK, EML4–ALK and DCTN1–ALK, and ALK-fluorescence in situ hybridization positivity. The clinical relevance of this gene fusion is not known. Blood tests and imaging to assess for other organ involvement should be considered. Retrospectively our cases showed no signs or symptoms of other organ involvement, and investigations were clear. Targeted ALK inhibitor therapy has shown responsive results in treating ALK-positive histiocytosis with multisystem involvement. Surgical resection has been successful in treating cutaneous disease, with no reported recurrence. As further cases of this rare condition come to light, its full clinicopathological and molecular features may become more apparent.
dermatology